Glancy
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Repros Therapeutics Inc.
(“Repros Therapeutics” or the “Company”) (NASDAQ: RPRX) concerning
possible violations of federal securities laws. The investigation
focuses on certain statements issued by the Company concerning the
Company’s business and financial prospects.
Please contact Lesley
Portnoy, Esq., at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
Repros Therapeutics is a development stage biopharmaceutical company
focused on the development of new drugs to treat hormonal and
reproductive system disorders. The Company is developing Androxal for
the treatment of low testosterone due to secondary hypogonadism.
On September 26, 2014, the Company announced that it had been granted a
Type B Pre-NDA meeting with the FDA in the first half of November
2014. According to the Company, Repros Therapeutics would seek guidance
on its planned New Drug Application (NDA) for Androxal during the
meeting. The press release also indicated that the Company believed that
the NDA for Androxal would be filed around the end of 2014. However, on
October 17, 2014, the Company revealed that the clinical information
provided to the FDA was not sufficient for a Type B Pre-NDA meeting and
that the November 2014 meeting with the FDA would be a Type C guidance
meeting instead. Following this news, shares of Repros Therapeutics
stock dropped nearly 40%, to a closing price of $3.61 per share on
October 17, 2014, on heavy trading volume.
If you purchased Repros Therapeutics shares, if you have information or
would like to learn more about these claims, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esq. of Glancy
Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, by toll-free telephone at (888) 773-9224 or by
telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2014